The investment round was led by US Venture Partners (USVP) and included participation from ARTIS Ventures, Mayo Clinic, Tokio Marine Future Fund, and existing investors such as Story Ventures, SemperVirens, and Metrodora Ventures, among others.
Delfina’s platform integrates with existing prenatal care teams to develop personalized, data-driven care plans. The company aims to address the U.S. maternal health crisis, which sees mortality rates significantly higher than in other developed nations, with Black women disproportionately affected. Delfina’s technology prioritizes equitable access to quality care and addresses social determinants of health that impact maternal outcomes.
The new funding will be used to support Delfina’s national expansion, enhance its predictive technology and interventional support, and reach more patients, particularly in underserved communities. The company’s goal is to become a leading technology partner for payors, providers, and families, working to improve maternal health outcomes and drive systemic change.
Delfina CEO Dr. Senan Ebrahim said, “This funding marks a significant milestone in Delfina’s fulfillment of our mission to solve the national maternal health crisis. We are grateful for the support of our investors and partners who share our commitment to improving outcomes for moms and babies. With this capital, Delfina will accelerate serving diverse populations, evolve our market-leading AI-powered predictive technology, and scale our impact nationally.”
USVP general partner Dafina Toncheva added, “Delfina’s care system is built on the most advanced machine learning technology that creates the most measurable impact for our healthcare system – particularly for Medicaid patients who are so underserved. We are excited to see the lifesaving application of this cutting-edge tech to maternal health. We are thrilled to join Delfina in delivering the future of pregnancy care to all families.”
